VBA
CBPO

Van Berkom & Associates’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Van Berkom & Associates’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,940
Closed -$1.11M – 64
2018
Q3 		$1.11M Sell
13,940
-4,694
-25% -$437K 0.03% 59
2018
Q2 		$1.85M Buy
+18,634
New +$1.61M 0.05% 56

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Van Berkom & Associates's CBPO Position: Q4 2018 in Review

Van Berkom & Associates sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2018, closing a stake of 13,940 shares — an estimated $1.11M sold.

Van Berkom & Associates first reported a position in CBPO in Q2 2018 and held it in 2 quarters. The position peaked at $1.85M in Q2 2018. 67 funds tracked by Wall St. Rank hold CBPO as of Q4 2018.

  • Van Berkom & Associates reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
  • Van Berkom & Associates sold 13,940 China Biologic Products Holdings, Inc. shares in Q4 2018, an estimated $1.11M.
  • Van Berkom & Associates first reported a position in China Biologic Products Holdings, Inc. in Q2 2018 and held it in 2 quarters.
  • Van Berkom & Associates's China Biologic Products Holdings, Inc. position peaked at $1.85M in Q2 2018.
  • 67 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2018.

Based on Van Berkom & Associates's 13F filing for Q4 2018, filed 13 Feb 2019.